Uterine cervix leukoplakia

Summary

Uterine cervix leukoplakia (MONDO:0004702) is a disease. A subtype of cervix disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine cervix leukoplakia
Mondo ID	MONDO:0004702
DOID	DOID:9043
ICD-10-CM	N88.0
NCIT	C3976
SNOMED CT	50923006
UMLS	C0269194
MedGen	124350
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	no

Also known as: cervical leukoplakia · cervix leukoplakia · cervix uteri leukoplakia · leukoplakia of cervix · leukoplakia of cervix (uteri) · leukoplakia of cervix uteri · leukoplakia of the cervix · leukoplakia of the cervix uteri · leukoplakia of the uterine cervix · leukoplakia of uterine cervix

Disease family

This is a subtype of cervix disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › cervix disorder › uterine cervix leukoplakia

Related subtypes (8): cervical polyp, hypertrophic elongation of cervix, cervicitis, cervix endometriosis, cervical incompetence, cervical metaplasia, cervix erosion, uterine cervix neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.